Vaxxinity (VAXX) Stock Price, News & Analysis

Company Overview

Vaxxinity, Inc. is a biotechnology company focused on developing active immunotherapies, including therapeutic vaccines, for chronic diseases. The company’s research is centered on treatments designed to stimulate the immune system to target disease-associated proteins while potentially offering longer-lasting effects than conventional therapies.

Vaxxinity’s pipeline has focused primarily on neurodegenerative disorders. Its programs have included UB-311, an investigational vaccine targeting amyloid beta for Alzheimer’s disease, and UB-312, an investigational vaccine targeting alpha-synuclein for Parkinson’s disease and related disorders. The company has also explored immunotherapy approaches for chronic pain and other conditions.

The company was formed from the United Neuroscience biotechnology platform and has conducted research and clinical development activities in the United States and internationally. Vaxxinity was co-founded by Mei Mei Hu, who has served as chief executive officer, and Lou Reese, who has held senior leadership roles within the company. Its products remain investigational and are subject to clinical testing and regulatory review.

Key Stats

• Today's Range: $0.00 to $0.04
• 50-Day Range: $0.00 to $0.06
• 52-Week Range: $0.00 to $0.20
• Volume: 367,198 shs
• Average Volume: 21,453 shs
• Market Capitalization: $12.68 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Vaxxinity Stock Analysis - MarketRank™

Vaxxinity scored higher than 2% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Vaxxinity.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Vaxxinity is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Vaxxinity is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

0.37% of the float of Vaxxinity has been sold short.

Short Interest Ratio / Days to Cover

Vaxxinity has a short interest ratio ("days to cover") of 34.44, which indicates bearish sentiment.

Change versus previous month

Short interest in Vaxxinity has recently decreased by 0.22%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Vaxxinity does not currently pay a dividend.

Dividend Growth

Vaxxinity does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

MarketBeat Follows

1 people have added Vaxxinity to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Vaxxinity insiders have not sold or bought any company stock.

Percentage Held by Insiders

64.06% of the stock of Vaxxinity is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

82.95% of the stock of Vaxxinity is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 3/27/2023
• Today: 10/21/2026
• Next Earnings (Estimated): 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:VAXX
• Previous Symbol: NASDAQ:VAXX
• CIK: 1851657
• Web: www.vaxxinity.com
• Phone: 254-244-5739
• Fax: N/A
• Employees: 90
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 126,750,000
• Free Float: 45,553,000
• Market Cap: $12.68 thousand
• Optionable: Not Optionable
• Beta: -74.42